Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Breast 1

Conditions

Osteosarcoma 7Bone Neoplasms 5Neoplasm Metastasis 4Sarcoma, Ewing 3Sarcoma 3Neuroblastoma 3Rhabdomyosarcoma 2Prostatic Neoplasms 2Pain 2Multiple Myeloma 2Breast Neoplasms 2Bone Diseases 2Spinal Cord Compression 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Renal Insufficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Osteoporosis 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Nerve Sheath Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms 1Myoepithelioma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1

Interventions

Zoledronic Acid 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fractures, Bone × Zoledronic Acid × Sarcoma × Clear all
NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Amgen

Phase 3 Completed
1,718 enrolled 22 charts
Other hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡